Floatz logo

GOSURANEMAB

Dementia Pugilistica

University of California, San Franciscomonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Dementia Pugilistica cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Molecular NeuroImaging
Phase 1CC
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
University of Texas Southwestern Medical Center
Early Phase 1C
FDDNP
University of California, Los Angeles
D
Intranasal Auto-M2-Bfs
Russian Academy of Medical Sciences
Phase 1/2NR

Same molecule, other indications

GOSURANEMAB is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
51 / 100
View asset →
tauopathyDormant
CC
Indicative ·
43 / 100
View asset →
corticobasal degeneration disorderDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →